Zacks: Analysts Expect Brainstorm Cell Therapeutics Inc. (BCLI) to Post -$0.10 Earnings Per Share
Brokerages expect Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) to post earnings per share (EPS) of ($0.10) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Brainstorm Cell Therapeutics’ earnings. Brainstorm Cell Therapeutics reported earnings per share of ($0.09) during the same quarter last year, which indicates a negative year over year growth rate of 11.1%. The firm is scheduled to announce its next earnings results before the market opens on Tuesday, October 17th.
On average, analysts expect that Brainstorm Cell Therapeutics will report full-year earnings of ($0.38) per share for the current fiscal year. For the next fiscal year, analysts anticipate that the firm will post earnings of ($0.42) per share. Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that follow Brainstorm Cell Therapeutics.
Brainstorm Cell Therapeutics (NASDAQ:BCLI) last issued its quarterly earnings data on Monday, August 14th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.10) by $0.04.
BCLI has been the subject of a number of recent analyst reports. Maxim Group set a $8.00 target price on shares of Brainstorm Cell Therapeutics and gave the company a “buy” rating in a research report on Saturday, July 22nd. ValuEngine raised shares of Brainstorm Cell Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, July 22nd.
A number of large investors have recently added to or reduced their stakes in BCLI. KCG Holdings Inc. increased its position in Brainstorm Cell Therapeutics by 4.6% during the 1st quarter. KCG Holdings Inc. now owns 41,537 shares of the biotechnology company’s stock valued at $177,000 after purchasing an additional 1,820 shares during the period. Sphera Funds Management LTD. acquired a new stake in Brainstorm Cell Therapeutics during the 2nd quarter valued at approximately $2,759,000. Finally, Vanguard Group Inc. increased its position in Brainstorm Cell Therapeutics by 2.8% during the 2nd quarter. Vanguard Group Inc. now owns 657,101 shares of the biotechnology company’s stock valued at $2,733,000 after purchasing an additional 17,657 shares during the period. 12.69% of the stock is owned by institutional investors and hedge funds.
Shares of Brainstorm Cell Therapeutics (NASDAQ BCLI) traded up 0.87% on Thursday, reaching $4.02. 25,712 shares of the company were exchanged. The company’s market cap is $75.75 million. Brainstorm Cell Therapeutics has a 12 month low of $2.06 and a 12 month high of $5.18. The company’s 50-day moving average price is $4.15 and its 200 day moving average price is $4.19.
About Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Brainstorm Cell Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics Inc. and related stocks with our FREE daily email newsletter.